摘要
濾泡性淋巴瘤（follicular lymphoma）為西方最常見之低惡性度淋巴瘤（indolent lymphoma），在過去20年間隨著rituximab的引進而存活顯著改善，但疾病反覆復發的特性仍使大多數病人被視為無法治癒，且目前仍缺乏預測病人早期惡化的工具。近來隨著技術演進以及病生理更進一步的理解，許多有潛力的藥物陸續出現。
參考文獻
Rivas-Delgado A, Magnano L, Moreno-Velázquez M, et al. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol 2019;184:753-9.
Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007;25:2426-33.
Sarkozy C, Maurer MJ, Link BK, et al. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. J Clin Oncol 2019;37:144-52.
Green MR. Chromatin modifying gene mutations in follicular lymphoma. Blood 2018;131:595-604.
Béguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013;23:677-92.